Cargando…
Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury
Several pre-clinical and clinical trials show that exogenous pulmonary surfactant has clinical efficacy in inflammatory lung diseases, especially ARDS. By infecting type II alveolar cells, COVID-19 interferes with the production and secretion of the pulmonary surfactant and therefore causes an incre...
Autores principales: | Cattel, Francesco, Giordano, Susanna, Bertiond, Cecilia, Lupia, Tommaso, Corcione, Silvia, Scaldaferri, Matilde, Angelone, Lorenzo, De Rosa, Francesco Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916525/ https://www.ncbi.nlm.nih.gov/pubmed/33657448 http://dx.doi.org/10.1016/j.resp.2021.103645 |
Ejemplares similares
-
Ozone therapy in COVID-19: A narrative review
por: Cattel, Francesco, et al.
Publicado: (2021) -
Exogenous surfactant therapy for acute respiratory distress in infancy
por: Moreno, M., et al.
Publicado: (1996) -
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2022) -
Exogenous Fungal Endophthalmitis: Clues to Aspergillus Aetiology with a Pharmacological Perspective
por: Lupia, Tommaso, et al.
Publicado: (2020) -
COVID-19: in the uncertainty, do not try this at home
por: Lupia, Tommaso, et al.
Publicado: (2020)